Boehringer Ingelheim, bioMerieux, & Evotec launch Aurobac to fight AMR

By Vinisha Joshi  | Date: 2022-07-07

Boehringer Ingelheim, bioMerieux, & Evotec launch Aurobac to fight AMR

Boehringer Ingelheim, a Germany based leading research-driven biopharmaceutical firm, along with bioMerieux, a global leader in vitro diagnostic and Evotec SE, the life science corporation have declared forming a joint venture to develop actionable diagnostics and next generation antimicrobials to battle Antimicrobial Resistance (AMR).

As per credible sources, Aurobac Therapeutics SAS- the joint venture firm- will bring together the top-notch abilities of these three founding firms for the development of a new accurate medicine approach, from diagnostics to cure.

Reportedly, the mission is to succeed in the battle against Antimicrobial Resistance which is a big public threat.

As per reports, routine surgeries such as hip replacement or caesarean sections can become life threatening, while complications from general diseases like injuries, diabetes or cuts can become tough to manage due to the increasing resistance towards antibiotics in the patients.

Michel Pairet, Board Member of Managing Directors and Innovation Unit Head at Boehringer Ingelheim stated that Antimicrobial Resistance or increase in the antibiotic-resistance infections is at present a predominating universal crisis.

Michael mentioned that antibiotic resistance kills nearly 1.27 million people every year globally, and as per the estimates, 10 million deaths across the world could result from Antimicrobial Resistance by 2050, making it possibly more fatal than cancer.

On the other hand, Werner Lanthaler, Chief Executive Officer, Evotec stated that the bleak potential of a post-antibiotic age has various causes but just one solution- the development of targeted, new, and effective antimicrobial therapies.

Werner commented that the team is thrilled to launch Aurobac with its partners at bioMerieux and Boehringer Ingelheim, to bring together the combined complementary powers.

It was further added that by leveraging multimodality approach of Evotec to infectious diseases, the firm is sure that Aurobac will be able to make the much-required progress to handle the universal challenge of Antimicrobial Resistance in the years to follow.

Speculations have it that Aurobac will work positively to shift the strategy related to antibiotic treatment regimens which currently relies majorly on empirical approaches using unfocused and broad-spectrum medicines.

Source Credits: -

About Author

Vinisha Joshi

Vinisha Joshi

As a qualified Engineering graduate, Vinisha Joshi takes pride in playing with words. Presently, she pens down insightful articles on business, core industry, technology, and the like for Thisisourtownrichmond in addition to other platforms. Creativity comes naturally...

Read More